Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
about
Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA.European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeletonEuropean data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patientsThe ins and outs of hematopoietic stem cells: studies to improve transplantation outcomes.Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftmentHuman Lacrimal Gland Gene ExpressionHematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in OncologyLong-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AMLPlerixafor in the treatment of stem cell mobilization failure; first experience in iran.Novel strategies for blood stem cell mobilization: special focus on plerixafor.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.Current clinical indications for plerixaforA plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program.Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean mulThe potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: current practice and remaining unmet medical needs.Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.How do we mobilize and collect autologous peripheral blood stem cells?Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study.New strategies for stem cell mobilization.Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation.Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.Remobilization of hematopoietic stem cells with high-dose methotrexate and cytarabine in patients with non-Hodgkin's lymphoma and multiple myeloma after failure to mobilize with chemotherapy and cytokines.Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.Partial engraftment following plerixafor rescue after failed sibling donor peripheral blood stem cell harvest.Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
P2860
Q27692619-98B702D8-C2B8-4386-A484-0CDCEFC91C6DQ33831680-31A20618-9AA3-41A5-90D8-8DDFFAF879B7Q34073741-3FB262B1-E771-47FC-A28F-B014006C9B27Q34159047-78023F42-FAE9-4D58-8762-555B4DB055D4Q34194325-BF02175F-F8F8-4385-8DB1-D8A583E04896Q34253548-A8FE8A71-352B-4556-A5DA-CBA54E34651EQ34432943-DFD2A9F6-6CF3-4929-A38F-23863626AE40Q34454624-516477C4-F796-47D7-B009-6402001AACACQ35041174-CD262A3E-5D52-4CC9-BC4E-BE84D0FBE2DFQ35475882-3ACE9EA0-ABDA-4BBF-B754-687D955C87CAQ36247483-C0463499-EAF2-4049-88D0-CDB0221FA2D8Q36428104-304936EE-1C21-4E8F-A5C9-3B06C28C9D8AQ36963203-D0842030-244B-4C43-B62A-DC4197C75B08Q37173297-9280E221-3DA0-4BBA-97F3-C095B736392FQ37268725-F9DF45DD-882C-40B3-BAFF-46CA2CF51C31Q37909447-D36E998B-1BCB-49D6-9D20-37E5B3BBAE69Q37921284-8255F915-02C8-42FE-A4B0-DAA340168BFBQ37943423-E68EB325-131F-4A47-A262-23D75ACE8339Q38160461-DB690650-F005-4AFC-BC74-E9B0531BE13FQ38177784-735DAB9E-2B69-4D5C-B313-D8FFAF11C027Q38194916-07E6A0FE-C197-4C2B-8B7D-8ABB1C66CE20Q38199707-B9F32A86-CFD6-4CF3-9650-F6191CB46ED5Q38200909-5CECC83D-97A5-4714-BA4D-CDF4AF993961Q38387292-6C50121B-2DE6-4A17-B547-B2F5CAC752C8Q38418369-9F021680-4417-4FFA-A01D-94AD78B15C7EQ38453666-8CCF1235-834C-4523-BDCC-C497A1BD8921Q38859426-D63D4C86-5A33-4F38-8518-2C1EE1EFC9CEQ38880504-0C84A293-3384-4AC8-89AD-F6F11B18DF37Q38978669-7C1BFF1B-6948-4F15-A1B3-213E2ACAF0A1Q39724267-2DDD531B-4371-4E80-BC13-09506EF317F2Q41003137-F6307EAE-14D6-4AF6-BBA1-8DCCB2E4B283Q41104670-47420C8F-AE5E-4CFC-80D6-A641DDF75261Q42184785-EBA95C2B-AFFF-4192-84CC-5E98BD25F96AQ42380588-6ABF2ADA-CC45-4BD6-BD7B-2164F3DF8AFDQ43714381-F4101C9A-D26B-479E-9845-6BF8A5A57E85Q43860084-9D31C1FA-E798-407F-B28A-DEF0D9A180B0Q44256421-66EC2456-CD46-4AD8-87AE-BC0DC0F3A451Q44556507-938867B7-1482-496C-BEC4-A4F3A8239067Q44592988-6151F12A-B513-4160-91B7-AB4F2AB81D91Q44736591-1B859C34-02C7-4A98-A42E-195517841FE9
P2860
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Plerixafor plus granulocyte CS ...... ts: EU compassionate use data.
@ast
Plerixafor plus granulocyte CS ...... ts: EU compassionate use data.
@en
Plerixafor plus granulocyte CS ...... ts: EU compassionate use data.
@nl
type
label
Plerixafor plus granulocyte CS ...... ts: EU compassionate use data.
@ast
Plerixafor plus granulocyte CS ...... ts: EU compassionate use data.
@en
Plerixafor plus granulocyte CS ...... ts: EU compassionate use data.
@nl
prefLabel
Plerixafor plus granulocyte CS ...... ts: EU compassionate use data.
@ast
Plerixafor plus granulocyte CS ...... ts: EU compassionate use data.
@en
Plerixafor plus granulocyte CS ...... ts: EU compassionate use data.
@nl
P2093
P2860
P356
P1476
Plerixafor plus granulocyte CS ...... ts: EU compassionate use data.
@en
P2093
C Martínez-Chamorro
H Achtereekte
J J Mateos-Mazón
J de la Rubia
K W Douglas
P2860
P2888
P356
10.1038/BMT.2010.54
P407
P577
2010-03-22T00:00:00Z
P5875
P6179
1028061284